疾病学术中心 > CHANGE网络教育中心 > 文献服务
网络课堂
网络课堂
网络课堂
网络课堂

网络课堂

change网络课堂

CHANGE网络课堂共有十个课件。均为国内知名专家撰写。 课程包括:总论课程(必学)和分论课程。

学习第一次通过80%的答题或者第一次学习通过低于80%但学习第二次通过90%的答题的会员, 就有机会获得由辉瑞制药有限公司提供的奖品。每月发放100份,全年发放1000份。 …… >> 进入网络课堂

热点讨论
热点讨论
热点讨论
热点讨论

热点讨论

热点讨论

您在临床工作中一定管理过炎症性肠病(IBD)吧!IBD包括克罗恩病与溃疡性结肠炎,传统的治疗方法对多数患者有效。然而随着近年来发病率的逐渐增高,病例数的不断增加,一些常规药物如SASP、美沙拉嗪、奥沙拉嗪等治疗效果差甚至无效的患者亦逐渐增多…… >> 详细

冒险天地
冒险天地
冒险天地
冒险天地

冒险天地

冒险天地

[神经内科]2007年.Mannitol for acute stroke

 

BACKGROUND: Mannitol is an osmotic agent and a free radical scavenger which might decrease oedema and tissue damage in stroke.

OBJECTIVES: To test whether treatment with mannitol reduces short and long-term case fatality and dependency after acute ischaemic stroke or intracerebral haemorrhage (ICH).

SEARCH STRATEGY: We searched the Cochrane Stroke Group Trials Register (searched December 2006), MEDLINE (1966 to January 2007), the Chinese Stroke Trials Register (searched November 2006), the China Biological Medicine Database (searched December 2006) and the Latin-American database LILACS (1982 to December 2006). We also searched the database of Masters and PhD degree theses at Sao Paulo University (searched January 2007), and neurology and neurosurgery conference proceedings in Brazil from 1965 to 2006. In an effort to identify further published, ongoing and unpublished studies we searched reference lists and contacted authors of published trials.

SELECTION CRITERIA: We included randomised controlled trials comparing mannitol with placebo or open control in patients with acute ischaemic stroke or non-traumatic intracerebral haemorrhage.

DATA COLLECTION AND ANALYSIS: Two review authors independently selected trials, assessed quality, extracted data, and performed the data analysis.

MAIN RESULTS: Three small trials, involving 226 participants, were included. One trial included patients with presumed ischaemic stroke without computerised tomography (CT) verification, and the other two trials included patients with CT-verified ICH. Data on the primary outcome measure (death and dependency) were not available in any of the trials. Death and disability could be calculated in the larger ICH trial without differences between the mannitol and control groups. Case fatality was not reported in the trial of ischaemic stroke. Case fatality did not differ between the mannitol and control groups in the ICH trials. Adverse events were either not found or not reported. The change in clinical condition was reported in two trials, and the proportion of those with worsening or not improving condition did not differ significantly between mannitol-treated patients and controls. Based on these three trials neither beneficial nor harmful effects of mannitol could be proved. Although no statistically significant differences were found between the mannitol-treated and control groups, the confidence intervals for the treatment effect estimates were wide and included both clinically significant benefits and clinically significant harms as possibilities.

AUTHORS' CONCLUSIONS: There is currently not enough evidence to support the routine use of mannitol in acute stroke patients. Further trials are needed to confirm or refute whether mannitol is beneficial in acute stroke.

 

     若您对此文有进一步需求,请与好医生医学策划庄建林联系。 邮箱:zhuangjianlin@mail.haoyisheng.com

北京健康在线技术开发有限公司

© 2000-2008 版权所有 京ICP证040426号 卫网审字[2001]第005号

Tel: 8008105790 服务信箱:webmaster@haoyisheng.com.cn